| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
, and IL-1ß in chronic progressive multiple sclerosis
Specialty Laboratories. Inc. (Drs. Peter and Boctor), Santa Monica, CA; and the Department of Neurology (Dr. Tourtellotte), VA Wadsworth Medical Center, Los Angeles, CA.
We measured interleukin-2 (IL-2), soluble IL-2 receptor (sIL-2R), tumor necrosis factor-alpha (TNF-
), and interleukin-1 beta (IL-1ß) by ELISA in paired sera and CSF from 50 chronic progressive multiple sclerosis (CPMS) patients during worsening disability, 19 patients with other neurologic diseases (OND), and in sera from 40 healthy volunteers. In the CPMS patients, 28% (14/50), 10% (5/50), 16% (8/50), and 6% (3/50) had elevated serum levels of IL-2, sIL-2R, TNF- and IL-1ß, respectively, compared with healthy controls. The only analyte we detected in the CSF was IL-2 in 1 CPMS patient (1/50, 2%). We also saw elevated serum sIL-2R in 16% (3/19) of OND patients. We found no significant difference in mean levels of serum sIL-2R between the 3 groups. Our study, the largest to date of CPMS patients, shows that serum and CSF levels of IL-2, sIL-2R, TNF-, or IL-1ß are not sensitive for, and the serum sIL-2R level is not specific for, CPMS. Therefore, measurement of these analytes will not be clinically useful for therapeutic or prognostic purposes in the majority of CPMS patients.
Address correspondence and reprint requests to Dr. James B. Peter, Specialty Laboratories, Inc., 2211 Michigan Avenue, Santa Monica, CA 90404-3900.
Received October 16,1989. Accepted for publication in final form June 15,1990.
This article has been cited by other articles:
|
|
 |
|
  S. Kurban, Z. Akpinar, and I. Mehmetoglu Letter To the Editor Multiple Sclerosis, April 1, 2008; 14(3): 431 - 432. [PDF]
|
|
|
|
 |
|
 K. W Selmaj Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system Ann Rheum Dis, November 1, 2000; 59(90001): i94 - 102. [Full Text] [PDF]
|
|
|
|
|
|
W.-X. Huang, P. Huang, H. Link, and J. Hillert Cytokine analysis in multiple sclerosis by competitive RT - PCR: A decreased expression of IL-10 and an increased expression of TNF-{alpha} in chronic progression Multiple Sclerosis, October 1, 1999; 5(5): 342 - 348. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Nicoletti, A. Nicoletti, S. Giuffrida, R. Di Marco, P. Meroni, K. Bendtzen, and M. Lunetta Sodium fusidate in Guillain-Barre syndrome: a case report J. Neurol. Neurosurg. Psychiatry, August 1, 1998; 65(2): 266 - 268. [Abstract] [Full Text]
|
|
|
|
|
|
M. Chofflon and B. Fellay Monitoring Multiple Sclerosis course and activity with TNF-alpha Multiple Sclerosis, June 1, 1998; 4(3): 188 - 192. [PDF]
|
|
|
|
 |
|
 B. W. van Oosten, F. Barkhof, P. E. T. Scholten, B. M. E. von Blomberg, H. J. Ader, and C. H. Polman Increased Production of Tumor Necrosis Factor {alpha}, and Not of Interferon {gamma}, Preceding Disease Activity in Patients With Multiple Sclerosis Arch Neurol, June 1, 1998; 55(6): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Sivieri, A M Ferrarini, and P Gallo Multiple Sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls Multiple Sclerosis, February 1, 1998; 4(1): 7 - 11. [Abstract] [PDF]
|
|
|
|
 |
|
 M. G. De Simoni, L. Terreni, R. Chiesa, F. Mangiarotti, and G. L. Forloni Interferon-{gamma} Potentiates Interleukin (IL)-6 and Tumor Necrosis Factor-{alpha} But Not IL-1{beta} Induced by Endotoxin in the Brain Endocrinology, December 1, 1997; 138(12): 5220 - 5226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Sandberg-Wollheim, E Ciusani, A Salmaggi, and F Pociot An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis Multiple Sclerosis, November 1, 1995; 1(3): 181 - 185. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
